Official Medicines Control Laboratory

Lehigh Valley Health Network Chooses Omnicell Solutions to Enhance Clinical and Operational Outcomes and Streamline Medication Management

Retrieved on: 
Thursday, October 22, 2020
Software, Pharmaceutical, Managed care, General Health, Health, Data management, Hospitals, Technology, Health, Articles, Health care quality, Pharmacy, Patient safety, Medical terminology, Lehigh Valley, Medical error, Adherence, Official Medicines Control Laboratory, LVHN, Omnicell

Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that Pennsylvania-based Lehigh Valley Health Network (LVHN) will be leveraging Omnicells industry-leading medication management platform of solutions to enhance efficiency, control, and safety of medication management.

Key Points: 
  • Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that Pennsylvania-based Lehigh Valley Health Network (LVHN) will be leveraging Omnicells industry-leading medication management platform of solutions to enhance efficiency, control, and safety of medication management.
  • LVHN is joining Omnicell on the journey to the Autonomous Pharmacy, a roadmap to develop a zero error, fully automated medication management infrastructure.
  • Lehigh Valley Cancer Institute, Lehigh Valley Heart Institute and Lehigh Valley Institute for Surgical Excellence physicians provide the most advanced treatments.
  • Over 6,000 facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety.

Omnicell to Release Third Quarter 2020 Earnings Results on October 27, 2020

Retrieved on: 
Tuesday, September 29, 2020
Data management, Health, Technology, Practice Management, Software, Pharmaceutical, Medicinal chemistry, Pharmacy, Symbols, Patient safety, Official Medicines Control Laboratory, Automation, Articles, Branches of science

Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will hold a conference call on Tuesday, October 27, 2020, to discuss the Companys Third Quarter 2020 financial results.

Key Points: 
  • Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will hold a conference call on Tuesday, October 27, 2020, to discuss the Companys Third Quarter 2020 financial results.
  • The conference call can be monitored by dialing 1-800-696-5518 within the U.S. or 1-706-758-4883 for all other locations.
  • The webcast can be accessed at: http://ir.omnicell.com/communications/events-presentations
    Available starting at 4:30 p.m. PT on October 27, 2020, through 11:59 p.m. PT on November 24, 2020.
  • Over 6,000 facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety.

Omnicell to Release Second Quarter 2020 Earnings Results on July 28, 2020

Retrieved on: 
Tuesday, July 21, 2020
Other Transport, General Health, Health, Transport, Pharmaceutical, Medicinal chemistry, Pharmacy, Symbols, Medication therapy management, Official Medicines Control Laboratory, Automation, Chemistry

Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will hold a conference call on Tuesday, July 28, 2020, to discuss the Companys Second Quarter 2020 financial results.

Key Points: 
  • Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will hold a conference call on Tuesday, July 28, 2020, to discuss the Companys Second Quarter 2020 financial results.
  • The conference call can be monitored by dialing 1-800-696-5518 within the U.S. or 1-706-758-4883 for all other locations.
  • The webcast can be accessed at: http://ir.omnicell.com/communications/events-presentations
    Available starting at 5:00 p.m. PT on July 28, 2020, through 11:59 p.m. PT on August 29, 2020.
  • Over 6,000 facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety.

Omnicell to Hold Virtual 2020 Annual Meeting of Stockholders

Retrieved on: 
Friday, May 1, 2020
Data management, Health, Technology, Hospitals, Software, Pharmaceutical, Internet, Viruses, Animal diseases, Laboratories, Official Medicines Control Laboratory, Middle East respiratory syndrome-related coronavirus, Veterinary medicine

Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced that due to the public health impact of the novel coronavirus (COVID-19) pandemic and to protect the health and wellbeing of its employees, stockholders and the broader community, the Company will hold its 2020 Annual Meeting of Stockholders in a virtual meeting format only, via live audio webcast.

Key Points: 
  • Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced that due to the public health impact of the novel coronavirus (COVID-19) pandemic and to protect the health and wellbeing of its employees, stockholders and the broader community, the Company will hold its 2020 Annual Meeting of Stockholders in a virtual meeting format only, via live audio webcast.
  • The virtual Annual Meeting will be held as planned on Tuesday, May 26, 2020 at 1:30 pm PT.
  • To attend the virtual Annual Meeting, please visit www.meetingcenter.io/238938008 .
  • Omnicell and the Omnicell logo are registered trademarks of Omnicell, Inc. in the United States and other countries.

Omnicell to Release First Quarter 2020 Earnings Results on May 7, 2020

Retrieved on: 
Tuesday, April 28, 2020
Data management, Health, Technology, Hospitals, Software, Pharmaceutical, Internet, Healthcare quality, Patient safety, Pharmacy, Automation, Official Medicines Control Laboratory, Contents, Articles

Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will hold a conference call on Thursday, May 7, 2020, to discuss the Companys First Quarter 2020 financial results.

Key Points: 
  • Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will hold a conference call on Thursday, May 7, 2020, to discuss the Companys First Quarter 2020 financial results.
  • The conference call can be monitored by dialing 1-800-696-5518 within the U.S. or 1-706-758-4883 for all other locations.
  • The webcast can be accessed at:
    Available starting at 5:00 p.m. PT on May 7, 2020, through 11:59 p.m. PT on June 18, 2020.
  • Over 6,000 facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety.

SHAREHOLDER ALERT: RLGY OMCL CARB NTAP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Retrieved on: 
Friday, September 6, 2019
Manufactured goods, Private Securities Litigation Reform Act, Wire, Carbonite, Goods economics), NetApp, Official Medicines Control Laboratory, Wire rope, Wong

NEW YORK, Sept. 06, 2019 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies.

Key Points: 

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Realogy, Reckitt Benckiser, and Omnicell and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, September 4, 2019
Companies, Reckitt Benckiser, Official Medicines Control Laboratory, Reckitt and Sons, Economy of the United Kingdom, Kingston upon Hull

reminds investors that class action lawsuits have been commenced on behalf of stockholders of Realogy Holdings Corporation (NYSE: RLGY), Reckitt Benckiser Group Plc (Other OTC: RBGLY), and Omnicell, Inc. (NASDAQ: OMCL).

Key Points: 
  • reminds investors that class action lawsuits have been commenced on behalf of stockholders of Realogy Holdings Corporation (NYSE: RLGY), Reckitt Benckiser Group Plc (Other OTC: RBGLY), and Omnicell, Inc. (NASDAQ: OMCL).
  • When the true details entered the market, the lawsuit claims that investors suffered damages.
  • Ultimately, Reckitt agreed to settle the federal investigations into its marketing and sale of Suboxone Film for $1.4 billion.
  • For more information on the Omnicell class action go to: https://bespc.com/omcl
    Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CannTrust, Realogy, Reckitt Benckiser, and Omnicell and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, August 19, 2019
Companies, Reckitt Benckiser, Official Medicines Control Laboratory, Reckitt and Sons, New York Stock Exchange, Industries, Economy of the United Kingdom

reminds investors that class action lawsuits have been commenced on behalf of stockholders of CannTrust Holdings, Inc. (NYSE: CTST), Realogy Holdings Corporation (NYSE: RLGY), Reckitt Benckiser Group Plc (Other OTC: RBGLY), and Omnicell, Inc. (NASDAQ: OMCL).

Key Points: 
  • reminds investors that class action lawsuits have been commenced on behalf of stockholders of CannTrust Holdings, Inc. (NYSE: CTST), Realogy Holdings Corporation (NYSE: RLGY), Reckitt Benckiser Group Plc (Other OTC: RBGLY), and Omnicell, Inc. (NASDAQ: OMCL).
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • Ultimately, Reckitt agreed to settle the federal investigations into its marketing and sale of Suboxone Film for $1.4 billion.
  • For more information on the Omnicell class action go to: https://bespc.com/omcl
    Bragar Eagel & Squire, P.C.

SHAREHOLDER ALERT: ZUO OMCL LB CAH: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Retrieved on: 
Tuesday, August 13, 2019
Manufactured goods, Private Securities Litigation Reform Act, Economy, Business, Zuora, Wire rope, Wire, Official Medicines Control Laboratory, Wong

NEW YORK, Aug. 13, 2019 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies.

Key Points: 

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CannTrust, Realogy, Reckitt Benckiser, and Omnicell and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, August 12, 2019
Companies, Reckitt Benckiser, Official Medicines Control Laboratory, Reckitt and Sons, New York Stock Exchange, Industries, Economy of the United Kingdom

reminds investors that class action lawsuits have been commenced on behalf of stockholders of CannTrust Holdings, Inc. (NYSE: CTST), Realogy Holdings Corporation (NYSE: RLGY), Reckitt Benckiser Group Plc (Other OTC: RBGLY), and Omnicell, Inc. (NASDAQ: OMCL).

Key Points: 
  • reminds investors that class action lawsuits have been commenced on behalf of stockholders of CannTrust Holdings, Inc. (NYSE: CTST), Realogy Holdings Corporation (NYSE: RLGY), Reckitt Benckiser Group Plc (Other OTC: RBGLY), and Omnicell, Inc. (NASDAQ: OMCL).
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • Ultimately, Reckitt agreed to settle the federal investigations into its marketing and sale of Suboxone Film for $1.4 billion.
  • For more information on the Omnicell class action go to: https://bespc.com/omcl
    Bragar Eagel & Squire, P.C.